



PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer


Evans-Axelsson, Susan¹, Abbott, Thomas², Fullwood, Louise³, Omar, Muhammad Imran⁴, Cavelaars, Marin⁵, Asimwe, Alex⁶, Roobol, Monique⁷, Ribal, Maria J.⁸, Auffray, Charles⁹, Devecseri, Zsuzsanna¹⁰, Smith, Emma Jane⁸, Van Hemelrijck, Mieke¹¹, MacLennan, Steven⁴, Horgan, Denis¹², Reich, Christian¹³, De Meulder, Bertrand⁹, Lancet, Doron¹⁴, Bangma, Chris⁷, Briganti, Alberto¹⁵, Tilki, Derya¹⁶, van Poppel, Hendrik¹⁷, Wirth, Manfred P.¹⁸, N'Dow, James⁹, Bjartell, Anders¹ and PIONEER Consortium*

1. Lund University, Sweden, 2. Astellas Pharma, USA, 3. Pinsent Masons LLP, UK, 4. University of Aberdeen, nited Kingdom, 5. The Hyve, The Netherlands, 6. Bayer AG, Germany, 7. Erasmus MC, The Netherlands, 8. EAU, Guidelines Group, The Netherlands, 9. EISBM, France, 10. Sanofi Genzyme, USA, 11. King's College London, UK, 12. EAPM, Belgium, 13. IQVIA, USA, 14. Weizmann Institute of Science, Israel, 15. Scientific Institute and University Vita-Salute San Raffaele Hospital, Italy, 16. University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Germany, 17. University Hospitals Leuven, Belgium, 18. University Hospital "Carl Gustav Carus", Technische Universität Dresden, Germany

About PIONEER


Prostate Cancer **DiagnO**sis and Treatme**Nt** Enhancement through the Power of Big Data in **EuRope** (PIONEER)

- An IMI2 funded public-private pan-European Network of Excellence for Big Data in Prostate Cancer.
- One of the EU's Big Data for Better Outcomes disease-specific projects.
- Consist of 32 stakeholders from across 9 countries.
- PIONEER is using a vast amount of available "big data" to improve screening, diagnosis and treatment of prostate cancer.



PIONEER's vision

PIONEERs vision is to re-orient the management and clinical practice of prostate cancer towards a more outcome-driven, value-based and patient-centric healthcare system for all European men living with prostate cancer.



PIONEER's 5-step approach

1. Identify critical evidence gaps in prostate cancer care through a prioritisation exercise including all stakeholders.
2. Identify core outcome sets for localised, locally advanced, and metastatic prostate cancer.
3. Collect, standardise and integrate existing 'big data' from prostate cancer patients across different stages of the disease into a single innovative data platform.
4. Use a unique set of methodologies and advanced analytical methods to answer the identified research questions.
5. Implementation of knowledge gained into clinical practice.

Target contributors




Individual databases are built on: Retrospective and Prospective single institute, Prospective multi-institute, Population-based cohorts, Randomised control trial cohorts, Retrospective and prospective multi-institutional

Identified data sources

Over 80 **European and non-European** prostate cancer-based databases have been identified.


EU-based data sources identified from:



Non-EU data sources identified from:




8 work packages with specific tasks



Results & Conclusions

- PIONEER has over 80 potential data sources identified
- Mapping **completed or in progress** for the following datasets:



- The PIONEER platform is being built using European and non-European datasets.
- Big data approaches using real-life data show great potential to fuel a new era in prostate cancer care and management.
- By harnessing the power of big data through collecting high-quality real-world data into a single innovative platform, health outcomes and healthcare systems in Europe can be maximized for men with prostate cancer.

How to contribute



PIONEER coordinator: James N'Dow, MD, PhD
✉ j.ndow@abdn.ac.uk

PIONEER Deputy coordinator: Anders Bjartell, MD, PhD
✉ Anders.Bjartell@med.lu.se

WP3 coordinator: Susan Evans-Axelsson, PhD
✉ Susan.Evans-Axelsson@med.lu.se

